BridgeMD
A clinical trial to evaluate safety, efficacy, and tolerability of abrocitinib in subjects with chronic hand eczema.
EU CTIS ID: 2023-504539-42-00
What this study is testing
To evaluate the efficacy of abrocitinib in subjects with moderate to severe CHE
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult subject, 18 years of age or older, at the time of consent.
- Subject has a history of moderate to severe CHE for at least 6 months prior to Day 1.
- Subject has refractory hand eczema.
- Subject has moderate to severe CHE at screening and Day 1, as defined by a hand PGA of 3 or 4.
- Contraceptive use by women of childbearing potential or their male partners during the study and until ≥ 4 weeks after the last study product administration.
You likely can't join if
- Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
- Subject has a history or has current active psoriasis.
- Subject has a history of eczema herpeticum within 12 months prior to screening, and/or a history of 2 or more episodes of eczema herpeticum in the past.
- Subject has any clinically significant medical condition (including psychiatric condition) or physical/laboratory/vital signs abnormality.
- Subject has known or suspected allergic contact dermatitis of the hands and is unable to avoid exposure to the causative allergen or subjects with suspected or expected changes in irritant or allergen exposures from screening through the end of the study
The study team makes the final eligibility decision.
Where it's taking place
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.